Open an account

TScan Therapeutics

TCRX · NASDAQ

$0.224+$0.0138 (+6.57%)TodayMarket closed ·
Prev close $0.2102

About TCRX

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 142 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The firm's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The firm is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The firm builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.

Employees
142
Headquarters
Waltham, Massachusetts
Listed
Jul 16, 2021
Sector
Health Care
Industry
Biotechnology
Website
tscan.com

TCRX key statistics

Market cap
15.18M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
671.60K
Volume
559.56K
Open price
$0.2144
High today
$0.2336
Low today
$0.2112
52 Week high
$2.55
52 Week low
$0.2014

TScan Therapeutics (TCRX) at a glance

TScan Therapeutics (TCRX) last traded at $0.224, with a market cap of 15.18M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.2112 and $0.2336. The current price is 6.1% above the day's low and 4.1% below its high.

Volume so far is 559.56K shares, in line with the average of 671.60K shares a day.

Over the past year TScan Therapeutics has ranged from $0.2014 to $2.55, and now sits 1% of the way up that range.

TScan Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.23 per share against an estimate of -$0.219.

The average analyst price target is $2.72, 1114.3% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 4 analyst ratings say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 5 analystsAvg $2.72
Low
$1.01
Now
$0.224
High
$6.30

TCRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 12.3% on average.

  1. Q3 FY24: reported -$0.25 per share against an estimate of -$0.2935
  2. Q4 FY24: reported -$0.30 per share against an estimate of -$0.2792
  3. Q1 FY25: reported -$0.26 per share against an estimate of -$0.2917
  4. Q2 FY25: reported -$0.28 per share against an estimate of -$0.2862
  5. Q3 FY25: reported -$0.28 per share against an estimate of -$0.3012
  6. Q4 FY25: reported -$0.18 per share against an estimate of -$0.246
  7. Q1 FY26: reported -$0.22 per share against an estimate of -$0.1754
  8. Q2 FY26: reported -$0.23 per share against an estimate of -$0.219

TCRX news

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Avi Kapoor

    Crude Oil Moves Higher; US Factory Orders Rise In July

  • Vandana Singh

    TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction

  • Avi Kapoor

    Dow Surges Over 200 Points; Ollie's Bargain Outlet Shares Gain After Q2 Earnings

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseGlobe Newswire

    TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

  • Press releaseBusiness Wire

    Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

  • Press releaseGlobe Newswire

    TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Similar companies

Companies in the same industry as TScan Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.